Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Envoy Medical, Inc. - Class A Common Stock Market Cap
The Envoy Medical, Inc. - Class A Common Stock (COCH) share price is expected to increase by 182.35% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered COCH. Price targets range from $5 at the low end to $8.75 at the high end. The current analyst consensus for COCH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned COCH 4 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Envoy Medical, Inc. - Class A Common Stock to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on COCH. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of COCH.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Tyler Bussian Brookline Capital | Buy | $9 | Initiates | Oct 14, 2024 |
| Edward Woo Ascendiant Capital | Buy | $8.75 | Maintains | Sep 3, 2024 |
| Edward Woo Ascendiant Capital | Buy | $8.5 | Initiates | Jun 24, 2024 |
| Frank Takkinen Lake Street | Buy | $6 | Maintains | Apr 3, 2024 |
| Carl Byrnes Northland Capital Markets | Outperform | Initiates | Dec 21, 2023 | |
| Frank Takkinen Lake Street | Buy | $3 | Initiates | Nov 28, 2023 |
When did it IPO
2023
Staff Count
34
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Brent T. Lucas Esq.
Market Cap
$46.4M
In 2023, COCH generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that COCH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - FDA approved a pivotal trial for a fully implanted cochlear implant, and AMA approved CPT codes for an already FDA-approved middle ear implant, signaling growth opportunities for the company.
Why It Matters - FDA and AMA approvals signal potential revenue growth and market expansion for the company, enhancing investor confidence in its future prospects and financial performance.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A study in Otology & Neurotology discusses early experiences and potential benefits of a new fully implanted cochlear implant, indicating advancements in hearing technology.
Why It Matters - Advancements in cochlear implants suggest increased market potential for medical device companies, potentially boosting stock prices and attracting investment in healthcare innovations.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Envoy Medical (NASDAQ: COCH) announced the European Patent Office granted it Patent No. 3858425 for its implantable modular cochlear implant system.
Why It Matters - The patent grant enhances Envoy Medical's competitive edge in the hearing health market, potentially increasing revenue and stock value through innovation and exclusivity.
Fri, 01 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The Acclaim® Fully Implanted Cochlear Implant presents a new option for patients with hearing loss, differing from current cochlear implant technologies.
Why It Matters - The Acclaim® Fully Implanted Cochlear Implant could capture market share in the hearing loss sector, potentially boosting revenue and stock value for the company involved.
Wed, 23 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Envoy Medical, Inc. (NASDAQ: COCH) will have CFO David R. Wells present a corporate overview at the LD Micro Main Event XVII from October 28-30, 2024, in Los Angeles.
Why It Matters - Envoy Medical's presentation at a prominent investor conference highlights its strategic initiatives and could influence market perception and stock performance.
Mon, 23 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Billionaire investor highlighted that next-gen wireless earbuds' hearing aid modes can integrate with Envoy Medical's fully implanted hearing devices.
Why It Matters - The integration of next-gen wireless earbuds with Envoy Medical's hearing devices highlights innovation in healthcare technology, potentially boosting Envoy's market position and attracting investor interest.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
